BRPI0411721A - derivados de tiazolilpiperidina como inibidores de mtp - Google Patents

derivados de tiazolilpiperidina como inibidores de mtp

Info

Publication number
BRPI0411721A
BRPI0411721A BRPI0411721-2A BRPI0411721A BRPI0411721A BR PI0411721 A BRPI0411721 A BR PI0411721A BR PI0411721 A BRPI0411721 A BR PI0411721A BR PI0411721 A BRPI0411721 A BR PI0411721A
Authority
BR
Brazil
Prior art keywords
mtp inhibitors
thiazolylpiperidine derivatives
thiazolylpiperidine
derivatives
radical selected
Prior art date
Application number
BRPI0411721-2A
Other languages
English (en)
Inventor
Philippe Guedat
Francois Collonges
Herve Dumas
Jean-Yves Ortholand
Jacques Decerprit
Jacques Barbanton
Richard J Foster
Peter Kane
Bernd Wendt
Original Assignee
Merck Patent Ges Mit Beschonkt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschonkt filed Critical Merck Patent Ges Mit Beschonkt
Publication of BRPI0411721A publication Critical patent/BRPI0411721A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"DERIVADOS DE TIAZOLILPIPERIDINA COMO INIBIDORES DE MTP". A presente invenção refere-se aos derivados de tiazolilpiperidina da fórmula geral (1): em que: A representa um radical selecionado dos radicais a1 e a2 abaixo: G representa uma ligação ou um radical divalente selecionado dos grupos g¬ 1¬, g¬ 2¬ e g¬ 3¬ abaixo: e R¬ 1¬, R¬ 2¬, R¬ 2¬<39>, R¬ 3¬, R¬ 4¬, R¬ 5¬, Y e Z são como definidos na descrição. Aplicação dos compostos da fórmula (1) para o tratamento de hipertrigliceridemia, hi-percolesterolemia e dislipidemia.
BRPI0411721-2A 2003-06-25 2004-06-02 derivados de tiazolilpiperidina como inibidores de mtp BRPI0411721A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307670A FR2856685B1 (fr) 2003-06-25 2003-06-25 Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2004/005931 WO2005003128A1 (en) 2003-06-25 2004-06-02 Thiazolylpiperidine derivatives as mtp inhibitors

Publications (1)

Publication Number Publication Date
BRPI0411721A true BRPI0411721A (pt) 2006-05-23

Family

ID=33515396

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411721-2A BRPI0411721A (pt) 2003-06-25 2004-06-02 derivados de tiazolilpiperidina como inibidores de mtp

Country Status (18)

Country Link
US (1) US7674803B2 (pt)
EP (1) EP1636218B1 (pt)
JP (1) JP4629666B2 (pt)
KR (1) KR20060024812A (pt)
CN (1) CN1809560A (pt)
AR (1) AR044909A1 (pt)
AT (1) ATE426599T1 (pt)
AU (1) AU2004253649B2 (pt)
BR (1) BRPI0411721A (pt)
CA (1) CA2531011C (pt)
DE (1) DE602004020223D1 (pt)
ES (1) ES2323463T3 (pt)
FR (1) FR2856685B1 (pt)
MX (1) MXPA05013521A (pt)
RU (1) RU2006101890A (pt)
TW (1) TW200518751A (pt)
WO (1) WO2005003128A1 (pt)
ZA (1) ZA200600690B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EA012607B1 (ru) * 2004-09-20 2009-10-30 4Сц Аг НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US20100267717A1 (en) * 2005-07-29 2010-10-21 4Sc Ag Novel Heterocyclic NF-kB Inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
JP2009502816A (ja) * 2005-07-29 2009-01-29 ４エスツェー アクチェンゲゼルシャフト 新規ヘテロ環状ＮＦ−κＢ阻害剤
BRPI0614834A2 (pt) * 2005-08-18 2011-04-19 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e usos destas
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EA200801838A1 (ru) * 2006-03-15 2009-02-27 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-kB
EP1834954A1 (en) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2007123269A1 (ja) 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
EP3719018A1 (en) 2006-04-25 2020-10-07 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008054702A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
US8318735B2 (en) * 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
JP5498168B2 (ja) * 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
PL2121660T3 (pl) 2007-01-25 2015-06-30 Du Pont Amidy grzybobójcze
DE102007047735A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
KR101494734B1 (ko) 2007-10-11 2015-02-26 아스트라제네카 아베 단백질 키나제 ｂ 억제제로서 피롤로[2,3-ｄ]피리미딘 유도체
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
CN101835764B (zh) 2007-10-24 2012-09-19 安斯泰来制药有限公司 唑甲酰胺化合物或其盐
CN101910165A (zh) * 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的噻唑衍生物
EP2402332A3 (en) 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
KR20100135952A (ko) 2008-04-30 2010-12-27 바이엘 크롭사이언스 아게 식물 보호제로서의 티아졸-4-카복실산 에스테르 및 티오에스테르
JP5785495B2 (ja) * 2008-10-01 2015-09-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 植物保護剤としてのヘテロシクリル置換チアゾール類
UY32285A (es) 2008-12-02 2010-06-30 Du Pont Compuestos heterocíclicos fungicidas
EP2404902A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
EP2272846A1 (de) * 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
US8557821B2 (en) * 2009-08-12 2013-10-15 Syngenta Crop Protection, Llc Microbiocidal heterocycles
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
WO2011051244A1 (de) 2009-10-30 2011-05-05 Bayer Cropscience Ag Heteroarylpiperidin und -piperazin derivate
WO2011076510A1 (en) * 2009-12-22 2011-06-30 Syngenta Participations Ag Pyrazole derivatives
EP2563786B1 (de) * 2010-04-28 2016-11-02 Bayer Intellectual Property GmbH Ketoheteroarylpiperidin und -piperazin Derivate als Fungizide
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8815775B2 (en) * 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
CN104987330B (zh) 2011-02-01 2019-04-05 拜耳知识产权有限责任公司 作为杀真菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
HUE028789T2 (en) 2011-02-02 2017-01-30 Vertex Pharma Pyrrolopyrazine spirocyclic piperidinamides as modulators of ion channels
EP2673272A1 (en) * 2011-02-10 2013-12-18 Syngenta Participations AG Microbiocidal pyrazole derivatives
MX2013009393A (es) * 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
AU2012229187B2 (en) 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
MY169449A (en) 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2015018027A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
WO2016086357A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
WO2018140730A1 (en) * 2017-01-27 2018-08-02 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
IL270217B2 (en) * 2017-04-28 2024-08-01 Texas Childrens Hospital Integrin-targeting nanoparticles, preparations containing them, methods for their production, and their uses
CN111196805A (zh) * 2018-11-17 2020-05-26 曲阜德禄生物科技有限公司 哌啶基噻唑甲酰胺类化合物合成方法与用途
EP4137496A4 (en) * 2020-05-12 2024-08-21 Beijing Greatway Pharmaceutical Tech Co Ltd COMPOUND FOR ADJUSTING NMDA RECEPTOR ACTIVITY, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
WO2024155864A1 (en) * 2023-01-20 2024-07-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Sprk1 inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015567A1 (de) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
JP2003529593A (ja) * 2000-04-04 2003-10-07 スミスクライン ビーチャム パブリック リミテッド カンパニー 抗菌剤として用いるための２−ヒドロキシムチリンカルバメート誘導体
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis

Also Published As

Publication number Publication date
EP1636218A1 (en) 2006-03-22
TW200518751A (en) 2005-06-16
KR20060024812A (ko) 2006-03-17
US20070054939A1 (en) 2007-03-08
WO2005003128A1 (en) 2005-01-13
AR044909A1 (es) 2005-10-05
US7674803B2 (en) 2010-03-09
ATE426599T1 (de) 2009-04-15
DE602004020223D1 (de) 2009-05-07
RU2006101890A (ru) 2007-07-27
AU2004253649A1 (en) 2005-01-13
JP2007506651A (ja) 2007-03-22
MXPA05013521A (es) 2006-03-09
ZA200600690B (en) 2007-05-30
ES2323463T3 (es) 2009-07-16
AU2004253649B2 (en) 2009-09-24
JP4629666B2 (ja) 2011-02-09
CA2531011A1 (en) 2005-01-13
FR2856685A1 (fr) 2004-12-31
CN1809560A (zh) 2006-07-26
EP1636218B1 (en) 2009-03-25
FR2856685B1 (fr) 2005-09-23
CA2531011C (en) 2012-10-09

Similar Documents

Publication Publication Date Title
BRPI0411721A (pt) derivados de tiazolilpiperidina como inibidores de mtp
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0410037A (pt) inibidores da fosfatidilinositol 3-cinase
CR10213A (es) Moduladores de la proteína quinasa aurora
BRPI0611923A2 (pt) modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
EA201071078A1 (ru) Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
ATE548374T1 (de) 2&#39;-fluor-2&#39;-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
BR0312658A (pt) Derivados de cinamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.